Last reviewed · How we verify
NCT05380557: ARTEMIS
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
trial testing Germline genetic testing in Pancreatic Adenocarcinoma in 2 participants. Terminated before completion.
6 September 2022
Quick facts
| Lead sponsor | Invitae Corporation |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 23 August 2021 |
| Primary completion | 6 September 2022 |
| Estimated completion | 6 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Germline genetic testing
Conditions studied
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Resectable Pancreatic Cancer — all drugs for Resectable Pancreatic Cancer →
Sponsor
Invitae Corporation
Who can join
18 and older, any sex, with Pancreatic Adenocarcinoma or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer. Second, we would like to learn more about patient experiences with genetic testing, such as patient understanding of the testing, health-related actions taken (or planned to take) as a result of testing, communication and action of family members based on test results, and psychological impact of testing. This research study involves allowing collection of tumor tissue (from a prior biopsy and/or surgery), a blood sample, and sending surveys to participants for their opinion on the impact of the genetic testing as well as clinicians for relevant baseline and medical history information.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05380557
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Invitae Corporation trials
Trials by the same sponsor.
- NCT05416710 — Universal Germline Testing in the Community · unknown
- NCT05447637 — PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05380557 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Invitae Corporation
- Last refreshed: 7 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05380557.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing